43 completed, 30 recruiting, 23 unknown, 18 terminated. 151 Phase 2, 20 Phase 1, 6 Phase 3.
Follow Gastric Adenocarcinoma: new trials by email Literature Review of Gastric Adenocarcinoma trials Research Report on Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer Neoadjuvant chemotherapy, Olanzapine - Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Not yet recruiting | University of Illinois at Chicago | 26 | 2026-09-01 | 2026-08-21 |
| Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Tagitanlimab - ESCC, Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 75 | 2026-08-31 | 2026-07-14 |
| Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma Retlirafusp Alfa, Oxaliplatin, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 21 | 2026-08-30 | 2026-07-17 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Denikitug, Nivolumab, Ramucirumab - HER2-negative, Gastroesophageal Junction | Phase 2 | Recruiting | Gilead Sciences | 120 | 2026-08-07 | 2026-09-21 |
| Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Fruquintinib - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 45 | 2026-07-31 | 2026-07-09 |
| Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma BHB810 - Gastric Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | BigHat Biosciences, Inc. | 164 | 2026-07-16 | 2026-10-20 |
| Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma serplulimab, Placebo - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center, Japan | 136 | 2026-07-15 | 2026-08-05 |
| HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Hyperthermic Intraperitoneal Chemotherapy, Serplulimab, S-1 - Locally Advanced Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 48 | 2026-07-13 | 2026-10-22 |
| Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. Oxaliplatin, Capecitabine, Tislelizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Ming Liu | 52 | 2026-07-01 | 2026-06-18 |
| Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma fruquintinib + sintilimab + SOX, Sinitilimab+SOX - Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Sichuan University | 120 | 2026-06-15 | 2026-06-22 |
| Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer Tafolecimab plus Sintilimab combined with SOX - Gastric Adenocarcinoma, Esophagogastric Juction Cancer | Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 30 | 2026-06-05 | 2026-06-02 |
| Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Yale University | 54 | 2026-06-02 | 2026-09-08 |
| Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma Alternative Postoperative Treatment Regimen, Original Treatment Regimen, Postoperative Observation - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 405 | 2026-06-01 | 2026-05-22 |
| Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Iparomlimab and Tuvonralimab Injection (QL1706), S-1, Oxaliplatin - Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Yongxu Jia | 34 | 2026-05-10 | 2026-09-09 |
| Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer Retlirafusp alfa + Apatinib + Nab-paclitaxel - Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 50 | 2026-05-05 | 2026-05-28 |
| Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma Chemotherapy, Targeted Systemic Therapy, Immunotherapy - Esophageal Cancer, Gastric (Stomach) Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 290 | 2026-04-29 | 2026-09-10 |
| SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer SHR-1701, apatinib, S-1 & Oxaliplatin - Gastric Adenocarcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2026-04-03 | 2026-07-16 |
| A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer Tunlametinib+PD-1 mAb - Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 76 | 2026-04-01 | 2026-04-02 |
| Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study Adebrelimab, XELOX, SHR-8068 - Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2026-01-30 | 2026-01-27 |
Showing 20 of 151. Sign in to see all of them.
Stomach Neoplasms (53) · Adenocarcinoma Of Esophagus (26) · Esophageal Neoplasms (14) · Adenocarcinoma (13) · Neoplasm Metastasis (8) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (7) · Small Cell Lung Carcinoma (7) · Squamous Cell Carcinoma of Head and Neck (7) · Esophageal Squamous Cell Carcinoma (6) · Carcinoma, Hepatocellular (5) · Colorectal Neoplasms (5) · Gastrointestinal Neoplasms (5) · Pancreatic Neoplasms (5) · Carcinoma, Ovarian Epithelial (4)
Neoplasms (79) · Neoplasms by Site (73) · Digestive System Diseases (69) · Digestive System Neoplasms (69) · Gastrointestinal Diseases (64) · Gastrointestinal Neoplasms (59) · Stomach Diseases (52) · Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (33) · Carcinoma (31) · Head and Neck Neoplasms (22) · Esophageal Diseases (20) · Adenocarcinoma (11) · Carcinoma, Squamous Cell (11) · Pathologic Processes (11)
Oxaliplatin (36) · Capecitabine (25) · Docetaxel (19) · Fluorouracil (19) · pembrolizumab (16) · Paclitaxel (13) · Leucovorin (12) · Ramucirumab (12) · S 1 (combination) (12) · Cisplatin (10) · Nivolumab (9) · Irinotecan (7) · Surgical Procedures, Operative (7) · Trastuzumab (6) · XELOX (6)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (4) · Samsung Medical Center (4) · Shanghai Zhongshan Hospital (4) · Eli Lilly and Company (3) · Fujian Cancer Hospital (3) · Gilead Sciences (3) · National Cancer Center Hospital East (3) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · Sun Yat-sen University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Akeso (2) · Assistance Publique - Hôpitaux de Paris (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)
United States (63) · China (40) · South Korea (15) · France (14) · Spain (9) · United Kingdom (9) · Australia (8) · Canada (7) · Germany (7) · Italy (7) · Japan (7) · Belgium (6) · Taiwan (6) · Turkey (Türkiye) (4) · Czechia (3)
Kohei Shitara, MD (3) · Andrew Blakely, M.D. (2) · Kiran Turaga, MD (2) · Manish Shah, MD (2) · Thierry Alcindor, MD, MSc (2) · Tianshu Liu, Doctor (2) · Afsaneh Barzi, MD (1) · Alexandre Brind'Amour, MD (1) · Anish Thomas, MD (1) · Ashwin Somasundaram, MD (1) · Aslam Ejaz, MD (1)
PMID 35623069, PMID 16822992, PMID 21444866, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26541586, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 28760152, PMID 29543932, PMID 30786188, PMID 30911859, PMID 30982686, PMID 31189049, PMID 31236579, PMID 31239311, PMID 31302344, PMID 31765987, PMID 32556731, PMID 32946924, PMID 33492986, PMID 33494793, PMID 33613701, PMID 33741442, PMID 33792646, PMID 33986123, PMID 34893523, PMID 35048809, PMID 35101941, PMID 35728046, PMID 35790315, PMID 36569905, PMID 37037952, PMID 37270871, PMID 37689733, PMID 37699333, PMID 37817565, PMID 38366886, PMID 38573643, PMID 38762353, PMID 38788174, PMID 38823034, PMID 39406730, PMID 39432867, PMID 40117530, PMID 40210967, PMID 40239627
2014 (3), 2018 (2), U10CA180820 (2), 2016 (1), 2023 (1), 2025 (1), P30CA008748 (1), P30CA014089 (1), P30CA016056 (1), P30CA072720 (1), U10CA180821 (1)